Group 1 - The company has conducted its 10th share buyback announcement in December, repurchasing 190,000 shares at a price of HKD 5.13 per share, totaling approximately HKD 1 million [1] - Cumulatively, the company has repurchased 3.34 million shares in December, with a total expenditure of around HKD 17 million, indicating strong confidence in its intrinsic value and long-term development [1] - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration and innovation [1] Group 2 - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its strong operational capabilities and market recognition in the health insurance sector [1] - The company has been elected as the vice-chair unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1] - Financially, the company has shown positive signs of improvement, with revenue maintaining steady growth and nearing breakeven in its mid-term results for the 2026 fiscal year, attributed to improved gross margins and operational efficiency [1] Group 3 - Analysts suggest that the company's frequent buyback actions reflect a judgment of its current stock price being undervalued and indicate financial strength to support future strategic investments [2] - The continuous buybacks and recent developments send a positive signal to the market, aligning with the trend of deep integration of artificial intelligence and healthcare [2] - The company's established barriers through deep layout and innovative practices are making its long-term investment value increasingly clear as performance inflection points approach [2]
医渡科技12月以来第10次回购 持续传递发展信心